Effect of the Antioxidant Lipoic Acid in Aortic Phenotype in a Marfan Syndrome Mouse Model

Table 1

Evolution of echocardiographic parameters in WT and MFS mice with 1, 3, and 6 months of age.

	WT1 ()	MFS1 ()	WT3 ()	MFS3 ()	WT6 ()	MFS6 ()
Ao/BW (mm/mg)	51 ± 3	73 ± 4^a	54 ± 3^b	67 ± 3^a,c	47 ± 1^b,d	63 ± 3^a,c,e
LVEDD (mm)	3.3 ± 0.1	3.3 ± 0.1	3.2 ± 0.1	3.1 ± 0.1	3.3 ± 0.1	3.5 ± 0.1
LVESD (mm)	2.0 ± 0.1	2.0 ± 0.1	1.8 ± 0.1	1.7 ± 0.1	1.9 ± 0.1	2.0 ± 0.1
IST (mm)	0.9 ± 0.1	0.8 ± 0.1	0.6 ± 0.1	0.7 ± 0.1	0.7 ± 0.1	0.9 ± 0.1
PWT (mm)	0.7 ± 0.1	0.7 ± 0.1	0.7 ± 0.1	0.8 ± 0.1	0.7 ± 0.1	0.9 ± 0.1
FS (%)	39 ± 2	43 ± 2	44 ± 2	44 ± 2	41 ± 1	43 ± 2
EF (%)	76 ± 2	80 ± 2	80 ± 2	81 ± 2	78 ± 1	79 ± 2
E/A ratio	2.1 ± 0.1	1.1 ± 0.1^a	1.9 ± 0.1^b	1.2 ± 0.1^a,c	1.9 ± 0.1^b,d	1.2 ± 0.1^a,c,e

WT: wild type; MFS: Marfan syndrome; 1: 1 month of age; 3: 3 months of age; 6: 6 months of age; Ao/BW: aortic root diameter index; LVEDD: left ventricular end-diastolic diameters; LVESD: left ventricular end-systolic diameters; IVST: interventricular septal thickness; PWT: posterior wall thickness; FS: fractional shortening; EF: ejection fraction; E/A: E/A waves; ^a versus WT1; ^b versus MFS1; ^c versus WT3; ^d versus MFS3; ^e versus WT6.